Paddy Ryan

Nutriband Financials

Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3

ORLANDO, FL / ACCESSWIRE / Dec 5, 2022 — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the third quarter ended October 31, 2022. Key Highlights: Generated record quarterly revenue of $620,000, up 118% over Q3 2021 Revenue for nine-months ended October 31, 2022, was $1,552,074, …

Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3 Read More »

Nutriband Inc to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

Orlando FL, Dec 2, 2022 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announces that Gareth Sheridan, CEO, will be presenting at the RHK Capital Disruptive Growth Conference in New York City on Monday, December 5 at 10:20 AM.  Mr. Sheridan will present a corporate overview with a specific focus on the Company’s AVERSA technology and market …

Nutriband Inc to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022 Read More »

Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA™ Abuse Deterrent Transdermal Technology Patent

ORLANDO, FL / ACCESSWIRE / Dec 1, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) announced that the Canadian Intellectual Property Office (CIPO) has granted Canadian patent No. 2,937,649, entitled “Abuse and Misuse Deterrent Transdermal Systems,” with an issue date of November 1, 2022. This patent protects Nutriband’s AVERSA™ transdermal abuse deterrent technology being developed to prevent the …

Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA™ Abuse Deterrent Transdermal Technology Patent Read More »

Nutriband Supports Newly Published CDC Opioid Prescribing Guidelines

New guidelines reiterate need for abuse deterrent technologies and call for enabling clinicians to provide comprehensive pain management including appropriate use of opioid medications ORLANDO, FL / ACCESSWIRE / November 8, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) supports the new United States Centers for Disease Control and Prevention (CDC) clinical practice guideline entitled “CDC Clinical Practice …

Nutriband Supports Newly Published CDC Opioid Prescribing Guidelines Read More »

Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive Agreement

ORLANDO, FL / ACCESSWIRE / October 27, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), today announced that it has signed an exclusive manufacturing agreement with Fleur Marché for its CBD and Botanical Patch lines. Nutriband Inc.’s wholly owned contract manufacturing subsidiary, Active Intelligence will act as exclusive manufacturer for the lines of products. Founded in 2019 …

Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive Agreement Read More »

Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Conference

ORLANDO, FL / ACCESSWIRE / October 26, 2022 / Nutriband Inc. (the “Company”) (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that its subsidiary, 4P Therapeutics LLC (“4P Therapeutics”), has conducted a Phase 1b clinical study for Sorrento Therapeutics, Inc. (“Sorrento”) (NASDAQ:SRNE) with results to be presented at the American College of Rheumatology (ACR) Convergence 2022 Conference on November …

Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology Conference Read More »

Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24

ORLANDO, FL / ACCESSWIRE / October 17, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) (“Nutriband” or the “Company”) today announced that it has accepted an invitation as a guest speaker for the 2023 Transdermal and Microneedle Conference to be held in London on January 23 and 24. The Company’s presentation will be on ‘Improving existing transdermal technologies …

Nutriband Inc. Invited to Present at the 2023 Transdermal and Microneedle Conference in London on January 23 and 24 Read More »

Nutriband with Kindeva Drug Delivery demonstrate enhanced abuse-deterrent characteristics for Aversa™ Fentanyl

ORLANDO, Fla., September 7, 2022 – Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) with Kindeva Drug Delivery have demonstrated enhanced abuse deterrence kinetics of the Company’s patented lead product, Aversa™ Fentanyl, an abuse-deterrent fentanyl transdermal system, with their development and manufacturing partner, Kindeva Drug Delivery.  Studies at Kindeva Drug Delivery have demonstrated that Nutriband’s proprietary transdermal aversive coating …

Nutriband with Kindeva Drug Delivery demonstrate enhanced abuse-deterrent characteristics for Aversa™ Fentanyl Read More »

Nutriband Inc. Announces Application for Dual Listing on Upstream

ORLANDO, FL / ACCESSWIRE / October 3, 2022 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) (“Nutriband” or the “Company”) today announced that it has begun the application process to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex (“Horizon”) and MERJ Exchange Limited (“MERJ”). The planned dual …

Nutriband Inc. Announces Application for Dual Listing on Upstream Read More »